A Phase 3, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Kala Pharmaceuticals, Inc.
- Enrollment
- 901
- Locations
- 81
- Primary Endpoint
- Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)
Study Overview
Brief Summary
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).
Detailed Description
This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have a documented clinical diagnosis of dry eye disease in both eyes
Exclusion Criteria
- •Known hypersensitivity or contraindication to the investigational product(s) or components
- •History of glaucoma, IOP>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.
- •Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within 30 days prior to screening.
- •In the opinion of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.
Arms & Interventions
KPI-121 0.25% Ophthalmic Suspension
Intervention: KPI-121 Ophthalmic Suspension (Drug)
Vehicle of KPI-121 0.25% Ophthalmic Suspension
Intervention: Vehicle (Drug)
Outcomes
Primary Outcomes
Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)
Time Frame: Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.
Change From Baseline/Visit 2 (Day 1) Ocular Discomfort Severity at Visit 4 (Day 15) in the Subgroup of Participants With More Severe Ocular Discomfort
Time Frame: Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15)
Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline.
Secondary Outcomes
- Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)(Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15))
- Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) Using 7 Day Mean(Baseline/Visit 2 (Day 1) to Visit 4 (Day 15))
- Change in Conjunctival Hyperemia Scores at Visit 4 (Day 15) by Alternate Assessor(Baseline/Visit 2 (Day 1) and to Visit 4 (Day 15))
- Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 3 (Day 8)(Baseline/Visit 2 (Day 1) to Visit 3 (Day 8))
- Change From Baseline/Visit 2 (Day 1) in Corneal Fluorescein Staining Score at Visit 4 (Day 15)(Baseline/Visit 2 (Day 1) to Visit 4 (Day 15))